Trial Profile
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Myocardial infarction; Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms EARLYmyo-LVT
- 30 May 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2023.
- 11 Mar 2020 Status changed from not yet recruiting to recruiting.
- 10 Dec 2019 Planned number of patients changed from 520 to 280.